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The fungus, Hericium erinaceus, has outstanding chemical properties, displaying health 
benefits in digestive, hepatic, and nervous tissues.  Its ease of accessibility and use makes it one 
of the most common substances used for treatment in Eastern medicine.  More and more recent 
research is confirming the incredible health benefits of this fungus, especially the impact that is 
seen on nervous tissue growth and recovery post-treatment.  Such neurite outgrowth and myelin 
sheath regeneration could illustrate the beginning of the cure to lifelong neurodegenerative 
diseases such as Multiple Sclerosis.  In this first-of-its-kind study, we cultured and differentiated 
fetal rat neural stem cells while treating the samples with varying concentrations of aqueous 
extract of Hericium erinaceus mycelium.  The cells were then harvested and lysed at various 
time points as the proteins were isolated and purified prior to analysis by LC-ESI mass 
spectrometry.  A proteomic analysis was conducted where statistically significant changes in 
protein expression were observed between the control groups and the treated trials of both time 
points.  While our initial targets of interest were not found, an up to 4-fold increase in protein 
expression was seen in a group of Histone H1 variants following treatment with Hericium 
erinaceus.  These Histone H1 variants are known to be linker histones which interact with the 
core histone bead and play a role in chromatin remodeling.  It is clear that Hericium erinaceus 
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plays a role in increasing the protein expression of Histone H1 variants which could lead to 
downstream effects yet to be revealed.  This exploratory research should serve as a helpful 
launching point for those determined to understand the underlying mechanisms behind this 
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CHAPTER 1: INTRODUCTION 
 
The nervous system is arguably the most complex biological system in our body.  There 
are many different types of cells and molecules that play vital roles in maintaining the health and 
wellbeing of the system.  In vertebrates, the nervous system is divided into two categories: the 
central nervous system (CNS) and peripheral nervous system (PNS).  The CNS is composed of 
the brain and spinal cord, whereas the PNS consists of the peripheral nerves and ganglia that 
stem from the brain and spinal cord.  There are two different cell categories in the nervous 
system, which include neurons and neuroglia (glia).  Neurons are the nerve cells that send 
electrical signals, known as action potentials, throughout the human body which control muscle 
cell contraction and relaxation.  Glial cells are supporting cells that play auxiliary roles and keep 
the overall environment healthy and proper for the neurons.  Neurons can also be supported by 
neuropeptides known as neurotrophic factors.  There are many neurotrophic factors that are 
involved in the regulation of growth, maintenance, proliferation, and survival of nerve cells, but 
the most common one that supports the growth of certain target neurons is known as nerve 
growth factor (NGF).  NGF plays a crucial role in a lot of nervous tissue development and is a 
subject of interest in many studies.  After many years of research, various protein markers have 
been visualized and have been used to determine the developmental state of nervous tissue.  
During development, all nervous tissue begins as neural stem cells which then differentiate into a 
variety of different neuronal cell types.  Nestin is the most widely known of these protein 
markers and is mostly only found in undifferentiated neural stem cells.  Other markers include 
neuron-specific enolase and fibrillary acidic protein, which is commonly observed inside glia.  
These markers are typically visualized during the quantitative analysis stages of research19.  
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While there are multiple kinds of neurons and glial cells, oligodendrocytes are the largest glial 
cells and play an irreplaceable role.  Oligodendrocytes are glial cells in the central nervous 
system that generate myelin, an important sheath that is responsible for enveloping neurons and 
ensuring proper action potential propagation.  They are aligned in rows between the nerve fibers 
of white matter and are close to the somata of neurons in gray matter.  The cytoplasmic processes 
of oligodendrocytes typically extend to multiple axons at once and wrap themselves around the 
length of the axon until multiple lamellas are formed.  These cells and the myelin they generate 
are presumed to be majorly affected in patients suffering from Multiple Sclerosis (MS). 
Overview of Multiple Sclerosis 
There are many neurological diseases in today’s world that are currently not curable, one 
of which is Multiple Sclerosis.  MS is a demyelinating disorder in which the immune cells 
invade the CNS to remove myelin debris, but overdo it and cause neuron and oligodendrocyte 
death which leads to physical, mental, and psychiatric impairment problems1.  White matter 
infiltration by our nervous system’s immune cells is the focal point of the pathology of MS17.  
The immune cells most responsible for the inflammatory processes that occur during the onset 
and progression of MS are CD4-positive T lymphocytes; however, monocytes, macrophages, 
neutrophils, and B lymphocytes are also involved.  While it was previously thought that the 
human brain does not change much after the first stages of development, it is now common to 
come across research showing the brain demonstrating structural and functional plasticity 
throughout the course of human life.  This brain plasticity is affected when these infiltrating 
immune cells secrete various factors that control and regulate neuronal function and signal 
formation in neuronal synapses18.  While Multiple Sclerosis is not an inherently deadly disease, 
patients suffering from MS typically have a reduced life expectancy.  Initially, non-durable 
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remyelination occurs which typically leads to neurological function recovery in the short-term.  
As time progresses, however, the pathological changes become dominated by widespread 
microglial activation associated with extensive and chronic neurodegeneration, the clinical 
correlate being progressive accumulation of disability15.  Paraclinical investigations show 
abnormalities that indicate the distribution of inflammatory lesions and axonal loss, interference 
of conduction in previously myelinated pathways, and intrathecal synthesis of oligoclonal 
antibody15.  Cellular and secretory activity of infiltrating leukocytes contributes to the creation of 
these inflammatory demyelinated lesions in the white matter of the brain.  The gray matter of 
patients with MS is also affected, leading to motor, sensory, visual, and cognitive impairment 
with the ability to memorize and learn being severely impacted18.  MS is a chronic condition that 
cycles between relapses and remissions.  The remission periods can last up to years, but 
symptoms flare up again eventually.  Multiple Sclerosis is sometimes more specifically referred 
to as Relapsing-remitting MS because of this. 
The current immunotherapies inhibit further demyelination, but do not act to enhance 
remyelination1.  Licensed disease-modifying agents reduce the frequency of new episodes but do 
not reverse fixed deficits and have questionable effects on the long-term accumulation of 
disability and disease progression15.  These treatments are also very expensive.  The cost-
effectiveness of a few disease-modifying drugs from a US societal perspective was analyzed and 
the results illustrated that dimethyl fumarate was the most preferred therapy to manage relapsing-
remitting multiple sclerosis3.  In 2014, the average annual medication cost of dimethyl fumarate 
was about $47,71816.  Between 2011 and 2015, the annual disease-modifying therapy (DMT) 
cost per MS patient increased from $26,772 to $43,606, a 13.0% average annual growth rate16.  
When comparing DMT users to non-DMT users, the annual health care cost per DMT user was 
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74% higher in 2011 ($50,352 vs $28,881), increasing to more than double in 2015 ($70,683 vs 
$29,821)16.  In the United States, the prevalence of MS has been presumed to be approximately 
100/100,000 people2.  Baldassari et al. describes in great length the therapeutic strategies being 
developed to promote myelin repair22.  Almost all cells in the nervous system are potential 
targets as drug manufacturers try to modulate cellular activity and environment to promote 
myelination and to inhibit demyelination.  There have been several laboratories that identified 
compounds which promote endogenous oligodendrocyte progenitor cell (OPC) function.  
Mesenchymal stem cell transplantation, high-dose biotin treatment, and protein pathway 
blocking are treatment methods that have been tested and are currently being explored some 
more due to the difficulty of successful implementation and monitoring in vivo.  Other drugs 
such as dopamine antagonists, atypical antipsychotics, thyroid hormone inducers, and 
testosterone stimulators are also currently being investigated in clinical trials for remyelination 
potential in MS.  Baldassari’s group also describes multiple methods of screening and assessing 
myelin integrity: positron emission tomography, magnetization transfer imaging, myelin water 
imaging, and diffusion tensor imaging.  There are also indirect ways of measuring myelin 
integrity: neurite orientation dispersion and density imaging, functional MRI, and magnetic 
resonance spectroscopy.  These forms of measurement will become more accurate as the field 
focuses more on repairing myelin instead of simply trying to halt demyelination, but as of right 
now, the major difficulties involve lack of accurate biomarkers and lack of specificity when 
tracking affected myelin.  It is important to fully understand the mechanism of action of 




Chemical Properties and Effects of Hericium erinaceus 
There may be a cheaper and more effective alternative on the horizon hiding inside a 
fungus.  Hericium erinaceus (HE), also known as Lion’s Mane, is a medicinal mushroom that 
contains neurotrophic and neuroprotective properties and has been widely consumed in Asian 
countries such as China and Japan4.  The first account of this mushroom being consumed dates 
back to 264 A.D. on Taiwan Island where the natives ate houtougeng (translated to monkey head 
thick soup) and considered the soup to be beneficial in neutralizing the ill-effects of alcoholic 
beverages5.  This mushroom is widely found in Asia, Europe, and northern temperate latitudes 
where beech and oak trees grow6.  Even with modern technology and transportation methods, 
there is an unfortunate lack of H. erinaceus consumption and utilization in North America.  The 
American species, H. americanum is also not commonly consumed. 
As any fungus, HE is composed of mycelium and fruiting bodies.  The powder of this 
crushed mushroom must be boiled in hot water to successfully extract the active compounds 
responsible for the health benefits experienced when consumed.  These active compounds come 
in many forms including hericenones, erinacines, and polysaccharides, to name a few.  
Hericenones are a group of aromatic compounds that have previously been found in the fruiting 
bodies of HE.  There were multiple aromatic compounds in this category that were isolated and 
purified by multiple researchers and the studies also revealed some anticancer properties tied to 
these compounds21.  Hericinones, however, failed to stimulate NGF gene expression in primary 
cultured rat astroglial cells and 1231N1 human astrocytoma cells23.  Li et al. describes erinacines 
as groups of cyathin diterpenoids that show biological activities as stimulators of NGF 
synthesis24.  To date, 15 erinacines (erinacines A-K and P-S) have been identified and further 
investigations have demonstrated that eight of them have various neuroprotective properties, 
18 
such as enhancing NGF release (erinacines A-I), reducing amyloid-β deposition, increasing 
insulin-degrading enzyme (IDE) expression (erinacines A and S), or managing neuropathic pain 
(erinacine E), while others are either being currently discovered or have different 
pharmacological activities24.  Li’s group concludes by stating that erinacine A is effective in 
reducing neurodegenerative disease-induced cell death, but because there have been no studies 
illustrating erinacine A’s crossing of the blood-brain barrier, it is hard to say how effective this 
compound will prove to be when consumed orally.  Beneficial polysaccharides have also been 
discovered and analyzed.  A polysaccharide EP-1 isolated from HE mycelia culture 
demonstrated antioxidant activity and prevented oxidative stress induced by H2O2 through 
mitochondrial dependent apoptotic pathways in gastric mucosa epithelial cells20.  A 
heteropolysaccharide (HEP-S) was isolated from the fruiting bodies of Hericium erinaceus and 
was observed to function as an immunostimulator to stimulate both the innate and adaptive 
immune responses in mouse cells25. 
H. erinaceus has been reported to illustrate incredible health benefits for the body’s 
digestive, immune, circulatory, and nervous systems.  Helicobacter pylori is a bacteria found in 
the stomach and is the main pathogenic factor of chronic gastritis, peptic ulcers, and 
adenocarcinoma of the distal stomach7, but its growth can be inhibited by using ethanol extracts 
and ethyl acetate fractions of HE8.  The exopolymer produced in submerged mycelial culture of 
HE has been shown to significantly reduce the plasma triglyceride, total cholesterol, low-density 
lipoprotein cholesterol, phospholipid, and liver total cholesterol level in rats, implying that it has 
hypolipidemic effects9,10.  There is a plethora of benefits to the nervous system such as, but not 
limited to, peroneal nerve recovery after crush injury11, coordination of neuron functions 
associated with complex neurodegenerative diseases6, and enhanced myelination in mature 
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myelinating fibers12.  Another study has also found that HE can activate the synthesis of nerve 
growth factor (NGF)13.  The stimulation of this neurotrophic factor can be beneficial in 
increasing the neurite outgrowth in a nervous system trying to combat a neurodegenerative 
disease.  Most importantly and according to a study cited by many, aqueous extract of this 
mushroom has been shown to improve and expedite the process of myelination in nerve cells14.  
This commonly cited study by Kolotushkina et. al. examined the effects of applying H. erinaceus 
extract to cultures of newborn WISTAR rat cerebellums.  When this group added the extract to 
their cells, they noticed no drastic changes in the development of nerve and glial cells, but the 
number of lamellae in the myelin sheaths did increase at a faster rate during development than 
untreated groups14.  This activity, in theory, can directly counter the demyelination of nerves as 
seen in patients with Multiple Sclerosis.  There are not many studies that cover this subject 
which make it difficult to find other studies that concur with the findings of this one.  To our 
knowledge, there were no studies completed beforehand analyzing the proteomic contents of 
nerve cells in vitro being treated with Hericium erinaceus.  Proteome analysis of the mushroom 
itself was conducted recently where mass spectrometry was used to identify a total of 2543 
unique proteins in the H. erinaceus genome26.  We can use the information from this study to 
help in our proteomic analysis, but the change in protein levels of rat fetal neural cells after 
treatment of H. erinaceus remains to be analyzed for the first time.  Therefore, analyzing the 
proteomic contents of these neural cells treated with this mushroom can lead to uncovering more 






Proteomics is the large-scale study of proteins and requires the use of a variety of 
techniques stemming from fields such as molecular biology, biochemistry, and genetics.  One 
vital technique, known as mass spectrometry, is utilized when analyzing a large amount of 
proteins at once.  After isolating, purifying, and breaking down the proteins of interest into 
smaller peptides, the sample is fed into a mass spectrometer where the now-accessible peptides 
are charged and turned into precursor ions through techniques like Electrospray ionization (ESI).  
Mass spectrometry is used to measure the mass-to-charge ratio of these ions that are pulled 
through the mass spectrometer machine by an oppositely charged current.  These are measured 
by a mass analyzer to generate what is known as a MS1 spectrum.  As the ions are analyzed, 
certain ones are pulled through the machine where they collide with inert gas and fragment into 
charged amino acids through a process called Higher-energy Collisional Dissociation (HCD).  
These fragments are analyzed a second time by either a different mass analyzer or the same one 
from before, generating a MS2 spectrum which we can further investigate using specific 
computer software.  This information allows investigators to see exactly what peptides were 
recognized by the mass spectrometry, making it possible to match discovered peptides to large 
databases in an effort to map back to proteins of interest.  The parameters for which precursor 
ions are sent to further dissociate are set on the machine’s software before the run begins.  The 
machine we used for our studies is known as the Thermo Scientific™ Orbitrap Fusion™ 
Tribrid™ mass spectrometer.  This machine’s mode of function and interior is further explained 




Purpose and Goal 
This study aimed to analyze the proteome of neural stem cells after H. erinaceus extract 
treatment.  The primary objective was to explore whether treatment of neuronal stem cells with 
H. erinaceus extract resulted in changes in gene expression profiles for proteins involved in the 
myelination synthesis pathway.  In our studies, we demonstrated that treatment of rat neuronal 
stem cells with H. erinaceus extract did not upregulate the expression of myelin basic protein or 
myelin expression factor 2, two known markers associated with myelin biosynthesis. However, 
they did reveal increased expression of histone 1 variants, suggesting treatment of neuronal stem 
cells with H. erinaceus extract leads to alteration in chromatin remodeling and gene silencing, 















CHAPTER 2: MATERIALS AND METHODS 
 
Neural Stem Cell Differentiation and Sample Preparation 
Rat Fetal Neural Stem Cells (Invitrogen™ N744-100) were expanded using T75 flasks.  
The T75 flasks were coated with a matrix consisting of CELLStart™ (Gibco™ A10142001) 
diluted 1:100 in D-PBS with calcium and magnesium. 560 mL of this matrix was made in total.  
14 mL of this matrix was used to coat each flask which were then incubated at 37°C in a 
humidified atmosphere of 5% CO2 in air for 1 hour before being stored until use.  Two different 
solutions were made: one for expanding the cells and one for differentiating the cells.  Cells were 
passaged using StemPro® NSC SFM complete medium consisted of KnockOutTM D-MEM/F-12 
with StemPro® NSC SFM Supplement, EGF, bFGF, and GlutaMAXTM-I (all from GibcoTM and 
ThermoFisher).  A mixture of penicillin and streptomycin was added to prevent bacterial and 
fungal contamination.  See Table 1 for the breakdown of concentrations.  The same medium 
lacking EGF and bFGF was used to differentiate the cells at P2.  The volume remained 
unchanged after removing these small amounts of growth factor.  To begin with, 4 of the 
previously matrix-primed T75 flasks were coated with cells and 20 mL of complete medium in 
each.  Each flask contained about 5 × 105 cells at this point.  After letting the cells grow for 24 
hours, the complete media was siphoned and replaced with fresh complete media to minimize the 
accumulation of cellular debris.  The cells expanded for a total of 3 days in Passage 0.  Photos 
were taken every day for three days using light microscopy (Leica DMI3000 B). After three 
days, two of the four T75 flasks were further expanded while the other two flasks were frozen 
and stored in liquid nitrogen.  Cells were passaged according to the manufacturer’s instructions, 
except for the centrifugation step where 400 × g was used instead of 300 × g (MAN0001642).  
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The cells were then distributed evenly and plated into 8 T75 flasks to begin P1.  The same 
procedure was followed and progress was recorded every day by light microscopy.  The P1 cells 
were allowed to approach confluency (2 days of growth) and these cells were split (P2).  P2 cells 
were split into smaller 100mm × 20mm plates and these cells were used as separate trials during 
the analysis.  6 mL of complete medium was used per plate which contained about 0.8 mL of 
cells.  Cells were expanded for 3 days while progress was recorded.  Three plates were harvested 
prior to the addition of the differentiation media.  These cells belonged to an undifferentiated 
neural stem cell group of trials.  The rest of the plates underwent an exchange of media where 
the complete medium was exchanged for one lacking EGF and bFGF (other concentrations 
remained the same as these small amounts did not affect volume significantly).  Different 
versions of the incomplete medium were made containing different concentrations of dissolved 
H. erinaceus mycelia (supplied by Real Mushrooms) to be used for the cultivation of the trials.  
The mushroom powder was weighed out and dissolved in the media lacking the growth factors.  
The amounts used and concentrations generated are listed in Table 2.  All proportions remained 
the same. Every remaining plate was coated with 10 mL of the differentiation medium.  The 
remaining plates were grouped into different trials with different timepoints.  Three replicates of 
the negative control, low concentration, medium concentration, and high concentration groups 
were harvested after 3 days of differentiation.  At this time, the media was exchanged for media 
containing the mushroom extract.  5 mL was siphoned off to prevent the cells from being 
exposed to air and 10 mL of fresh differentiation media was added.  The remaining three 
replicates of each group were harvested after 7 days of differentiation.  Light microscopy was 
used to record the progress of cell differentiation.  All cells were harvested and washed using the 
same procedure per plate.  7 mL of media was transferred to a conical tube using a sterile pipette 
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and cells were washed with 5 mL of D-PBS lacking Ca2+ and Mg2+.  The D-PBS was aspirated 
off and 1 mL of accutase was added to each plate.  Cells were rinsed with 4 mL of matching 
media which was then transferred to the same conical tube.  Cells were centrifuged at 400 × g for 
4 minutes and the supernatant was discarded.  The pellet was resuspended with 1 mL of cold D-
PBS and spun again.  This step was repeated once more and the resulting supernatant was 
removed.  The cell pellet was frozen at -80°C.  All cell subculturing protocols were carried out 
aseptically under a Laminar flow hood. 
 
Table 1 
Component Distribution for 100 mL StemPro® NSC SFM Complete Medium 
 
Component Concentration Amount 
KnockOutTM D-MEM/F-12 1X 97 mL 
GlutaMAXTM-I Supplement 2 mM 1 mL 
bFGF 20 ng/mL 2 μg 
EGF 20 ng/mL 2 μg 
StemPro® NSC SFM Supplement 2% 2 mL 
Penicillin + Streptomycin 0.5% 0.5 mL 


















Concentrations of H. erinaceus in 125 mL StemPro® NSC SFM Incomplete Medium 
 
H. erinaceus Trial Name Concentration Amount 
Low 0.1 mg/mL 12.5 mg 
Medium 0.25 mg/mL 31.25 mg 




In-solution tryptic digestion was performed to prepare samples for mass spectrometer 
analysis.  A total of 200 µL of 6 M urea/100 mM Tris buffer (pH 7.8) was used to lyse the cells.  
Sonication was also conducted as an additional measure to ensure complete cell lysis.  To help 
denature proteins, 5 µL of reducing reagent, 200 mM DTT, was added and the sample was mixed 
by gentle vortex.  After letting sit for 10 minutes in room temperature, 20 µL of alkylating 
reagent, 200 mM IAA, was mixed into the tube and vortexed.  After another 10 minutes, 20 µL 
of 200 mM DTT was mixed in and allowed to sit for 10 minutes at room temperature.  775 µL of 
sterile MilliQ water was added to each sample to dilute the urea concentration and create an 
environment where trypsin can retain its activity.  Initially, 3 µL of Trypsin Gold Solution (0.5 
mg/mL) was added and the digestion was carried out overnight at 37°C.  The next day, another 
1.5 µL of Trypsin was added and allowed to digest for another 2 hours.  The reaction was then 
stopped by adding 5.125 µL of 10% TFA.  
PierceTM C18 Spin Columns (Thermo ScientificTM No. 89873) were used to purify the 
samples.  The columns were activated with 50% ACN, equilibrated with 5% ACN + 0.5% TFA 
solution, and used according to the manufacturer’s instructions.  About 1 mL of sample was 
bound, washed, and eluted.  20 µL of elution buffer was run through the columns twice to 
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guarantee a thorough product.  This resulted in a 40 µL solution that would be stored and later 
used for analysis. 
Colorimetric Peptide Assay and Normalization 
Eighteen samples were analyzed by use of the Pierce Quantitative Colorimetric Peptide 
Assay (Thermo Scientific™ No. 23275).  Prior to this analysis, these samples were lyophilized 
and then resuspended with 15 µL of 5% ACN + HPLC grade water + 0.1% Formic Acid 
solution.  All reagents were made as per the manufacturer’s instructions and the protocol was 
followed stringently.  2 µL of each sample was mixed with 18 µL of autoclaved water before 
being mixed with the 180 µL of working reagent.  After running the software analysis, some 
discrepancies were visible between the biological replicates.  In order to maximize the amount of 
peptide binding to the mass spectrometer analytical column, the biological replicates with the 
higher peptide concentration were selected.  These samples were normalized with HPLC grade 
water + 0.1% Formic Acid to match the limiting concentration of one of the samples (the control 
for Day 3).  The concentrations and samples selected are illustrated in Table 3.  After 
randomizing the order in which they would be processed, the samples were inserted into the 
mass spectrometer to begin the proteomic analysis.  Every sample was injected twice at a volume 
of 25 µL per injection, creating technical replicates.  The second injections were treated as 













Observed Initial Concentrations of Chosen Samples and Post-Normalization Values 
 






Volume of Water 
Mixture (µL) 
3C2 174.495 1.74495 10 40 
7L1 200.901 1.74495 8.68 41.32 
7H2 213.293 1.74495 8.18 41.82 
3M2 236.433 1.74495 7.38 42.62 
NSC2 250.005 1.74495 6.98 43.02 
7M1 262.165 1.74495 6.65 43.35 
3L2 324.988 1.74495 5.37 44.63 
7C1 365.978 1.74495 4.77 45.23 
3H1 438.012 1.74495 3.98 46.02 
HeLa 155.022 - 20 80 
Note.  Samples are notated by the format of [Trial Day][Trial Group][Replicate Number].  For 
example, 3C2 is Day 3 Control no. 2.  NSC2 refers to the undifferentiated Nerve Stem Cells 
sample used.  HeLa cells were included to check for consistency during the Mass Spectrometry 
run every 24 hours.  Water mixture consists of HPLC grade water + 0.1% Formic Acid. All 
samples except for the HeLa cells were injected twice (25 µL per injection). The HeLa cells were 




Peptides were eluted from the C18 column and subject to electrospray ionization and the 
samples were analyzed using our Thermo Scientific™ Orbitrap Fusion™ Tribrid™ mass 
spectrometer. Individual samples were subject to approximately a 2 hr chromatographic run 
using a previously established X-calibur program. The entire running time on the mass 
spectrometer was about 72 hours.  A sample of HeLa cells was injected every 24 hours to 
confirm spray stability of the needle during the run.  The total volume of HeLa cells was divided 
into four injections for a total of 25 µL per injection.  Once completed, chromatography graphs, 
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MS and MS/MS data were generated.  Data were further analyzed through quantitative analytical 
software, such as Peaks Studio and Protein Scaffold 4. 
RT-qPCR Analysis 
 In order to complete reverse transcription and quantitative polymerase chain reaction 
analysis (RT-qPCR), total RNA was isolated, washed, and solubilized.  A standard Trizol RNA 
isolation procedure was done according to Invitrogen’s manual (Pub.No. MAN0001271 B.0).  
All samples were lysed with Trizol containing 60 µL of 100% chloroform and centrifuged to 
generate separate phases within tubes.  Each sample’s aqueous phase was transferred to a new 
tube and precipitated using 150 µL of 100% isopropanol along with centrifugation at 4°C.  The 
gel-like pellets that resulted were then washed three times 3 with 300 µL of 70% ethanol.  After 
vacuum-drying the pellets for about 20 minutes, the pellets were resuspended in 20 µL of 
RNase-free water.  The RNA yield for each sample was determined by use of the 
ThermoScientific™ NanoDrop 2000c Spectrophotometer and the appropriate absorbance values 
were recorded. 
 The purified RNA was then prepared for RT-qPCR analysis by mixing with the proper 
reagents from the PowerUp™ SYBR™ Green Master Mix (Applied Biosystems™).  The RNA 
was first diluted to a concentration of 12.5 ng/µL.  Then, the following mixture was produced: 4 
µL of 12.5 ng/µL RNA; 10 µL of 2x SYBR green dye; 0.2 µL QN SYBR green Reverse 
Transcriptase mix; 1 µL of 20x primer mix; 4.8 µL RNase free water.  Samples were analyzed 
for each of the five primers and technical duplicates were also generated.  Forward and reverse 
primers were mixed (see Table 4) and checked for their ability to amplify their specific amplicon 
beforehand using 2% agarose gel electrophoresis.  A 96-well plate was used to load 18 µL of 
each mixture and was then processed by the continuous fluorescence detector.    
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Table 4 
Primer Sequences for Histone H1 Family 
 


























Note. Melting Temperatures (MT) for both forward and reverse primers are shown. Primers are 


















CHAPTER 3: RESULTS 
 
Neural Stem Cell Differentiation 
Light microscopy was used to examine the process of growth and differentiation of the 
nerve stem cells.  Photos were taken every day in greyscale and monitored for healthy 
progression.  The Day 3 trial groups were compared to the Day 3 control and undifferentiated 
stem cells at Passage 2 (Figure 1).  A visible difference between the morphology of the stem 
cells and the morphology of the differentiated cells was seen (Figure 1).  The differentiated cells 
in both the control group and the trials seemed to successfully form neural connections typically 
seen in nervous tissue.  The morphology of the cells from the trials did not seem to significantly 
deviate from the control group, illustrating that the addition of the H. erinaceus extract did not 





Figure 1.  Comparison of morphology between undifferentiated stem cells and Day 3 Control 
and treatment groups using light microscopy.  The yellow measurement bar is set to 100 µm for 
reference.  The treated groups and undifferentiated stem cells are portrayed in 200x 
magnification while the Control group is portrayed in 100x magnification. 
 
 
The same could not be said about the Day 7 group.  In comparison to the Day 3 group, 
the Day 7 group illustrated more solid groupings of nerve cells and glia with more distinct crater-
like low-density spaces in between the formations (Figure 2) illustrating a progression in 
maturation.  A uniquely dense cluster of cells, similar to controls, was found when analyzing the 
Low Concentration trial for Day 7 as seen in Figure 2.  When comparing the Day 7 trials, the 
ones that were treated with the medium and high concentrations of H. erinaceus exhibited what 
seemed to be less specific condensed grouping of cells which resulted in less crater-like low-
density space compared to the low concentration and control trials, and which appeared to mimic 





Figure 2.  Comparison of morphology between undifferentiated stem cells and Day 7 control and 
treatment groups using light microscopy.  The yellow measurement bar is set to 100 µm for 
reference.  The treated groups and Control are portrayed in 100x magnification while the 
undifferentiated stem cells are portrayed in 200x magnification. 
 
  
Proteomic Analysis and Mass Spectrometry 
Prior to use for proteomic analysis, the grown cells from all samples were washed with 
D-PBS lacking Ca2+ and Mg2+ and detached at their respective time points with acutase, followed 
by cell lysis in urea.  Following crude lysate collection and tryptic digestion, samples were 
purified using C18 spin columns and checked for peptide concentration using Colorimetric 
Peptide Assay.  The initial concentrations were recorded (Table 3).  After normalizing the 
concentrations to the baseline concentration of sample 3C2, samples were inserted into the mass 
spectrometer and analyzed over a 4 day period.  Each individual sample was analyzed for about 
2 hours.  Chromatographic graphs were generated to illustrate the relative abundance of peptides 
eluting off of the column at every point in time. Similarities between retention time and relative 
abundance are best illustrated between the control and trial groups of the same day (Figure 3).  
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There are certain notable differences in the graphs, but for the most part, there is not much 
variation to be seen in the overall shape.  This implies that the samples were handled and 
processed properly with little error.  For the Day 3 group, there was a peak missing in 3C at 
roughly the 22.70 minute retention time that was visible in all the other trials in varying 
abundances (Figure 3).  The Day 7 control group seemed to differ from the Day 7 treatment 
groups, most notably in the end of the chromatographic run around 91-94 minutes.  There were a 
couple of peaks showing more abundance in the treated groups compared to the control, 
signifying that there may be proteins that are uniquely expressed and representative peptides are 
eluted off the column at that point that are not found in the control group.  It may also be the case 
that those same peptides might have simply been eluted at a different point in a spread out way.  
This is unlikely, however, since by looking at the overall curve of the 7C graph, it is hard to spot 
where these peaks could have shifted to.  Overall, these figures confirm our assertion that the 
samples analyzed display similar quantities of peptides, allowing us to carry on with further 
















Figure 3.  Raw chromatography files from the Thermo Scientific™ Orbitrap Fusion™ Tribrid™ 
mass spectrometer after completing the sample processing.  These graphs compare the relative 
abundance of peptide (y-axis) to the retention time (x-axis).  A: Day 3 Group color-coded and 
labeled.  B: Day 7 Group color-coded and labeled.  Note the difference in order from top to 
bottom between A and B. 
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Quantitative Proteomic Analysis 
Mass spectrometry data were analyzed using Protein Scaffold (Proteome Software, Inc.™ 
), a software algorithm designed for quantitative proteomics.  Within this software algorithm, 
MS/MS spectra were tallied up and normalized in preparation for quantitative comparison and 
analysis.  Protein sequences, statistical correlation, and probability percentages were illustrated 
among many other useful metrics. Prior to optimization, a total of 365,537 spectra were obtained 
from the combined 8 sets of data (Day 3 Control, Day 7 Control, Day 3 Low, Day 3 Medium, 
Day 3 High, Day 7 Low, Day 7 Medium, Day 7 High).  The protein threshold value, minimum 
number of peptides value, and peptide threshold value were modified.  As the software conducts 
the internal statistical analysis, it checks for the probability of a protein or peptide actually 
existing in the sample according to the registered and recognized spectra.  The protein and 
peptide thresholds are in reference to these probabilities.  For our analysis, protein and peptide 
thresholds were set to 95%, indicating that Scaffold would only display proteins and peptides 
that the algorithm calculated of having at least a 95% probability of being present in the samples.  
The minimum number of unique peptides used for protein identification was set to 2, which is 
commonly accepted by the proteomic community to confirm the presence of proteins.  These 
parameters narrowed the results and allowed for a more stringent and accurate observation of 
proteins that were most likely to be “real”.  These parameters also minimized the false discovery 
rate and dramatically lowered the chances of encountering false positives in the data.  After 
setting such parameters, there were a total of 648 unique proteins and 21,602 spectra found when 
comparing the Day 3 Control to the Day 3 Trial groups.  A statistical two-tailed T-test was 
conducted and found that 61 of these proteins were statistically significant with a p-value of less 
than 0.05.  Of these 61 proteins, 26 were expressed in higher quantities, up to a 4-fold difference, 
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in the Day 3 Control compared to the trials.  The rest of the 35 proteins were expressed in lower 
quantities, up to a 4-fold difference, in the Day 3 Control compared to the trials (Appendix A).  
The same statistical analysis was conducted for the Day 7 groups where a total of 1042 unique 
proteins and 37,541 spectra were found following analysis using the same parameters. After 
finding 193 statistically significant proteins, 64 of them were expressed in higher amounts, up to 
a 4-fold difference, in the Day 7 Control compared to the trials. The other 129 proteins were 
expressed in lower quantities, up to a 4-fold difference, in the Day 7 Control compared to the 
trials (Appendix B).  A final statistical analysis, ANOVA (p-value < 0.05), was conducted to 
illustrate significant variance between all three groups of trials (Controls vs Day 3 trials vs Day 7 
trials).  A total of 129 unique proteins across all samples were found to be statistically significant 
according to this analysis with respect to changes in protein expression (Appendix C).  Of these 
proteins, 36 were unanimously expressed in higher amounts, up to a 4-fold difference, in the Day 
3 and Day 7 trials when compared to the Control groups.  On the other hand, 17 proteins were 
expressed in lower amounts, up to a 4-fold difference, in the Day 3 and Day 7 trials when 
compared to the Control groups.  These proteins were researched one-by-one to find any 
correlation to previous studies about H. erinaceus or Multiple Sclerosis.  While there were no 
statistically significant proteins found that have a direct role in either of these subjects, there was 
a profound change seen in the expression of certain histones between the control groups and the 
trial groups.  There were multiple notable histones such as H2A, H1.1, H1.2, H1.3, H1.4, and 
H1.5.   Most of these histones were variants of the H1 family.  Differences in expression are 
visualized in Figure 4 where there was at least a 4-fold difference in normalized spectral counts 
between the control and trial groups.  The largest differences are visualized in Figures 4B, 4C, 
and 4D.  Simultaneously, the undifferentiated cells were compared to the controls to confirm that 
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differentiation was successful on a genotypic level.  Nestin, a protein expressed at high levels in 
neural stem cells and a widely employed marker28, was shown to be expressed less in the 





















(Figure 4 Continued) 
 
Figure 4.  Normalized total spectra vs biosample.  These graphs were exported as raw data from 
Protein Scaffold.  The raw number of Total Spectra is not as important as the comparison in 
values and changes between the groups of samples.  All histones significantly increased in 
expression when treated with H. erinaceus, regardless of elapsed days.  A: histone H2A Type 1-
C.  B: histone H1.4.  C: histone cluster 1 H1 family member d (histone H1.3).  D: histone H1.5.  
E: histone H1.1.  F: histone cluster 1 H1 family member c (histone H1.2). 
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Figure 5.  Normalized total spectra of nestin in controls vs nerve stem cells.  The lower amount 
of spectral counts in the controls implies that less of the marker protein is expressed in these 
samples. Based on this evidence, differentiation did successfully occur.  
  
The Protein Scaffold software also generated scatterplots after the ANOVA test was conducted 
(Figure 6).  The control group (Day 3 Control and Day 7 Control) was compared to the Day 3 
trials separately from the Day 7 trials.  Both graphs illustrated a similar pattern when comparing 
averaged normalized total spectra.  This demonstrated that there was little variation in the trials 
due to the different time points.  As a result, however; there was a clear significant difference 




Figure 6.  ANOVA test results of histones in controls vs trials.  The highlighted green box in 
both A and B refer to histone H1.4 simply for reference.  The numbers on both axes represent 
Total Normalized Spectra as an average in those groups.  The green boxes represent a protein 
that significantly shows more normalized spectra in a trial group than a control group and vice-
versa.  In this case, the six green boxes refer to the histones in Figure 4. 
 
The amino acid sequences of these proteins were also examined to see if there were any 
substantial differences in the order of amino acids that could further explain the specific function 
of these histone variants.  As illustrated in Figure 7, all of the six examined histone variants were 
rich in both arginine and lysine with minor variation in overall charge.  This was to be expected, 





Figure 7.  Recognized peptide sequences matched with a proteome database and mapped back to 
the histones of interest.  The amino acids highlighted in yellow are confirmed to match by 
available spectra data.  All peptides from each protein were examined, but only the best-matched 
peptide from each protein was chosen to be compared. 
 
Since we selected a neural cell line based on previous studies of myelin sheath 
regeneration being affected by H. erinaceus14, it was useful to look for any proteins that could 
correlate our results to these previous studies.  In our analysis, only one myelin related protein 
was found in every sample.  This protein, known as Myelin expression factor 2, did not show any 
significant variation (ANOVA) in expression between the control group, the Day 3 trials, and the 
Day 7 trials (p-value = 0.34).  The control for day 3 showed a drastically different result from the 
control for day 7 whereas the other groups did not show much variance within their respective 
groups.  Based on this data, we cannot make any solid conclusions, but it was interesting to see 
the decrease in normalized total spectra when going from the Day 3 group to the Day 7 group.  If 
it were true that Myelin expression factor 2 was being expressed less as time went on, then 
expression levels of myelin basic protein (MBP) would increase.  This is because Myelin 
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expression factor 2 is a transcriptional repressor for MBP.  MBP is one of the main components 
of myelin sheath so seeing an increase in expression of this protein would illustrate an increase in 
total myelination occurring.  The normalized total spectra data is illustrated in Figure 8. 
 
 
Figure 8. Normalized total spectra of myelin expression factor 2 in the analyzed samples. This 
data was not deemed statistically significant by the ANOVA test, but was still worth looking at 
as it could present a lead for future studies. 
 
Post-Translational Modifications 
Post-translational modifications (PTMs) have always been a talking point when it comes 
to histones.  Since many different studies have addressed specific PTMs, it was important to 
analyze the possible PTMs that were found in our samples to see if the affected charge and 
structure in the peptide sequence would affect histone binding and function.  Using a different 
program now in the form of Peaks Studio X, we compared our samples using a similar algorithm. 
In this software; however, we were capable of visualizing the proper PTMs at certain sites within 
the amino acid sequences of each peptide.  When comparing the controls to the trials, multiple 
amino acid sequences were found to be linked with the histone peptides.  Some of these 
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sequences had PTMs that would occur more often than others.  For example, when the five 
Histone H1 variants were processed, four of them showed sequences that were acetylated at the 
first serine in the amino acid chain (Figure 9).  This does not mean that all of these peptides were 
acetylated, but it does show that some were.  Further comprehension of Figure 9 shows that there 
were other modifications such as carbamylation and ubiquitination.  There was little PTM 
variation seen between the histones for the first 65 amino acids with Histone H1.1 and Histone 
H1.5 being the most different.  De novo peptides were fully matched and the confident 
modification sites were shown with a minimal ion intensity of 5%.  This means that a pair of 
major fragment ions (b and y ions) must be found showing fragmentation before and after the 


















Figure 9.  Amino acid sequences of the five variants of histone H1 with possible PTMs labeled 
at certain sites.  Not all copies of these peptides are modified, but there are some that were 
modified in the samples.  A: Histone H1.1.  B: Histone cluster 1 family member C.  C: Histone 
cluster 1 family member D.  D: Histone H1.4.  E: Histone H1.5.  Little variation is illustrated 
between B, C, and D for the first 65 amino acids.  Histone H1.1 and Histone H1.5 peptides were 




 Before the RT-qPCR analysis was conducted, the prepared RNA of every sample was 
measured for purity by calculating absorbance values through use of the NanoDrop™ 2000c 
Spectrophotometer (Thermo Scientific™).  These values are illustrated below in Table 5. 
 
Table 5 
RNA Absorbance Values 
 
Sample Concentration (µg/µL) A260/A280 A260/A230 
C3 1.9282 1.78 2.21 
L3 1.2177 1.75 2.25 
M3 0.8436 1.78 2.24 
H3 1.2680 1.86 2.08 
C7 1.1582 1.80 2.23 
L7 1.1262 1.81 2.20 
M7 1.0629 1.81 2.09 
H7 1.3195 1.84 2.01 
 
 
 Since the samples were confirmed to be pure enough by this data, the RT-qPCR analysis 
carried on with the use of a continuous fluorescence detector.  This machine generated curves 
that illustrated the relative fluorescence as the cycles carried on.  Forty cycles were completed 
according to the standard PCR specifications listed in the user guide (MAN0013511).  After the 
curves were generated, a cycle time threshold of 0.180 was set to compare how quickly the 
contents amplified between the different histone H1 variants.  Most of the variants exhibited the 
same basic trend where the curves of the treated groups would cross the threshold sooner than 
the curves of the control groups for both time points.  The (c)T values (cycle time values) were 
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typically lower for the treatment groups and a bit higher for the control groups, illustrating that 
generally there was more histone H1 variant RNA in the cells post-treatment with H .erinaceus 






























(Figure 10 Continued) 
 
Figure 10.  The difference in cycle time compared across the histone H1 variants. The equation 
is ΔCt = Cycle time of Trial - Cycle time of Control.  The day 3 trials were compared to the day 
3 control and the day 7 trials were compared to the day 7 control.  The threshold of 0.180 was 
crossed during the RT-qPCR analysis of each sample for every histone H1 variant.  Both time 
points are illustrated in each graph.  The more negative differences indicate more initial RNA in 
the sample for the depicted histone H1 variant as compared to the more positive differences 










CHAPTER 4: DISCUSSION 
 
Neural Stem Cell Differentiation 
 Nervous tissue is notorious for being very delicate and although we performed every step 
meticulously, there was always a chance for contamination or inefficient growth.  We kept this in 
mind as the results were processed.  We initially wanted to treat the neural stem cells with larger 
concentrations of H. erinaceus extract to rival studies published previously; however, this proved 
to be difficult as the H. erinaceus extract powder failed to completely dissolve when added to the 
incomplete medium.  After decreasing the concentrations through multiple iterations, the 
strongest concentration that could be completely dissolved in the medium (defined by no 
particles visible) was set to 0.5 mg/mL.  The other two weaker concentrations were chosen for 
relative ease of calculation.  After confirming that there were no particles to be seen in the 
mixture following addition of the powder, the mixtures were poured over a microfilter as another 
safety measure to ensure no contamination during the mixing process.  Unfortunately, some of 
the material that was filtered out of the solution seemed to be particles of H. erinaceus.  We were 
not able to measure the exact amount that did not pass through the microfilter and we did not 
know how this would affect our results.  We were unable to restart the procedure as the cells 
were already in the process of growing and our supply of media was running low.  It would have 
been ideal to run this experiment once more using different conditions, but due to financial and 
time restraints, we were limited to this path that we already started on.  Despite this hiccup, we 
decided to continue with the experiment as it was.  When observing the morphology of the 
differentiated cells under the electron microscope, little variation between the different 
concentrations of treatment groups was seen within the same day of trials.  The data analyzed 
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during the later stages of the proteomic analysis reinforces the lack of variation except for when 
it came to the dense clustering of the cells seen in the Low Day 7 trials.  The medium and high 
concentration counterparts did not exhibit such specific clustering and showed a broader 
distribution of cells with less clusters.  According to these signs, one would assume that these 
higher concentrations are affecting the differentiation in an impactful way.  However,  even with 
the unique clusters seen in the Low Day 7 trials, the proteomic data bolsters the fact that this 
interesting morphology does not significantly impact the expression of proteins.  It is unclear if 
this is due to insufficient concentration of H. erinaceus affecting the cells or if more time has to 
pass to visualize these differences more distinctly.  It may also be possible that H. erinaceus has 
no effect whatsoever on the morphology of the cells and that it may only affect gene and protein 
expression unrelated to external physical appearance. 
Normalization and Mass Spectrometry 
 Prior to running our samples through the mass spectrometer, we decided to lyophilize the 
samples in order to increase the concentration of protein.  This allows the mass spectrometer to 
register more effective scans.  During the colorimetric peptide assay, peptide concentration was 
recorded; however, one of the two biological replicates of each sample was more concentrated 
than the other and was chosen to be used for the mass spectrometry.  Using the sample with the 
lowest concentration of total peptides (3C2), we normalized the other samples so the total 
peptide concentration would be closely similar across the board (Table 3).  This was important to 
maintain consistency during the experiment.  Randomizing the order of the samples during the 
run was key in preventing the occurrence of unwanted bias and variables.  The samples were 
double-injected in order to create technical replicates.  The technical replicates of the samples 
were also randomized and did not go in the same order as the original samples.  A sample of 
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HeLa cells was injected multiple times in equal time intervals in between our samples to provide 
evidence for the machine’s consistency in spray pattern.  In essence, this functioned as a 
technical control to see if there were any issues with the mass spectrometer’s run itself.  No 
significant variation in spray pattern pattern was found, illustrating that the machine executed the 
procedure without issues.  The mass spectrometer generated chromatographs (Figure 3) that were 
used to validate our data and vet it before moving on with the software-based quantitative 
proteomic analysis.  The technical replicates generated identical chromatographs as those shown 
in Figure 3 and were not listed to avoid redundancy. 
Quantitative Proteomic Analysis 
 To ensure a False Discovery Rate (FDR) of less than 0.1%, certain parameters had to be 
set during the Scaffold analysis.  After setting the thresholds to the defined values mentioned in 
the Results section, we were able to achieve a point where we could analyze every peptide with 
extremely high confidence.  For measuring protein abundance, spectral counting is one of the 
most effective methods to use.  There is a very strong correlation between protein abundance and 
spectral counts30.  While another method of protein quantification, measuring ion peak intensity, 
is available for use, it typically has practical constraints when used for complex biological 
samples31.  Because of this, we used spectral counting for our analysis. However, it was vital to 
normalize the spectral counts in order to measure the variation between samples accurately.  The 
Scaffold program normalized protein spectrum counts by completing multiple calculations in a 
stepwise manner.  First, the total number of spectra in each biosample was calculated. Then, the 
average number of spectra across all biosamples was calculated.  Finally, the spectral count of 
each protein in every sample was multiplied by the average count over the biosample’s total 
spectral count.  An example of this calculation is illustrated by Table 6. 
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Table 6 
Example of Spectral Count Normalization in Scaffold 
 
Biosample A Spectral Count Biosample B Spectral Count  
Protein 1 12 Protein 1 8  
Protein 2 6 Protein 2 3  
Protein 3 4 Protein 3 3  
Total 22 Total 14 Total Average: 18 
Biosample A Normalized Biosample B Normalized  
Protein 1 10 Protein 1 10  
Protein 2 5 Protein 2 4  
Protein 3 3 Protein 3 4  
Note.  Biosample A protein spectral counts are multiplied by 18/22.  Biosample B protein 
spectral counts are multiplied by 18/14. 
  
The histones illustrated in Figure 6 had overall high normalized spectral counts.  Pairing 
this information with the significance resulting from the statistical analysis, these peptides made 
for our best targets in the final stages of our research.  It seems as though these linker histones 
could play a role in neural stem cell differentiation.  Histone H1 is the most variable of the 
histones and has multiple variants as seen in this study, but it also has strongly conserved regions 
which could explain the similar function between the variants32.  If one Histone H1 variant is 
being expressed at lower amounts, other variants show a compensatory increase in expression 
controlled by an unknown mechanism33.  However, if enough H1 subtypes are lost, embryonic 
stem cell differentiation is impaired and the silencing of pluripotency factors during DNA 
methylation mediation is interrupted.  This shows that modulating the levels of these linker 
histones and chromatin compaction may help in regulating stem cell pluripotency34.  Based on 
this information from previous studies, we initially believed that the increase in Histone H1 
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protein expression that is witnessed in Figure 6 correlated to an increase in embryonic stem cell 
differentiation and was resulting in a faster differentiation process.  To verify this, we sought out 
potential downstream targets that might be regulated by these changes in the histones.  These 
targets were markers that were previously discussed in other studies relating to the nervous 
system and differentiation.  If our initial theory was correct, then the markers for increased 
differentiation should increase in expression.  Lower levels would be illustrated in the control 
groups and higher levels would be illustrated in the treated samples.  We examined standard 
markers such as neuron-specific enolase (for neuron growth) and glial fibrillary acidic protein 
(for glial growth), but the results did not support our theory.  Levels of these markers were 
actually higher in the control group, demonstrating that differentiation was not occurring at a 
faster rate in the treatment groups since neuronal and glial synthesis was not accelerating 
according to these keystone markers.  There is still room for improvement on this end as not 
even a major proteomic marker of myelin sheath synthesis, MBP, was found during the 
proteomic analysis.  Considering that it is capable of being found by mass spectrometry37, our 
protocol could be refined to better isolate this protein from within the lipid membrane of 
myelin38.  The lack of this protein in the analyzed sample is odd considering that the 
transcriptional repressor for it was found and changes in protein expression levels were seen as 
the days passed.  This may be due to the time limits implemented during this study being too 
short and the protein itself not forming in enough abundance yet.  Although there was glial 
growth as illustrated by the darker spots during light microscopy, perhaps not enough mature 







 Another software, Peaks Studio X (Proteome Software, Inc.™) was used to confirm the 
data found in Scaffold.  Peaks Studio X uses a slightly different algorithm to calculate the False 
Discovery Rate and other metrics; however, all the results still pointed towards the previously 
discussed histones.  More importantly, this software allowed us to analyze the effect of post-
translational modifications on the Histone H1 family.  It is known that Histone H1 variants are 
filled with many lysine and arginine residues and are therefore positively charged.  This strong 
positive charge will allow for tight binding to DNA during chromatin compaction.  These linker 
histones can act as transcriptional repressors or promoters when this binding occurs.  However, 
more studies link these histones to the function of local repression35.  Post translational 
modifications such as methylation and acetylation make it more difficult for these linker histones 
to tightly bind to the wound chromatin due to the decrease in positive charge and the structural 
change of the histones.  These changes particularly impact the terminal parts of the protein 
sequence which are thought to be involved in binding of chromatin proteins regulating 
transcriptional activity36.  Our results are illustrated in Figure 9, showing post-translational 
modifications that have occurred at certain parts in the sequence for a certain number of Histone 
H1 peptides. Not all H1 peptides experienced post-translational modifications, but the ones that 
did experienced them in various regions.  The most similar ones being Histone H1.2 (family 
member C), H1.3 (family member D), and H1.4 with a lysine residue at position 64 and/or 65 
experiencing ubiquitination.  Histone H1.1 is most likely experiencing significantly different 
modifications because it is considered a specific variant for thymus, testis, spleen, lymphocytic, 
and neuronal cells36.   Although the Histone H1 proteins act as regulators of individual gene 
transcription through chromatin remodeling, nucleosome spacing, and DNA methylation, not 
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much methylation was witnessed in our data.  The charge of the proteins would remain 
overwhelmingly positive and there would not be a large enough shift in molecular structure seen 
to affect the tight binding of these linker histones significantly.  Still, this is worth exploring in 
the future to calculate the actual difference in binding between modified histones and non-
modified histones. 
Conclusion and Future Directions 
 This exploratory research should serve as a gateway for future projects in the field of 
proteomics, H. erinaceus, and alternative medicine.  There are still many unknowns about the 
pathways within the nervous system and how it is affected when treated with H. erinaceus. 
Based on previous studies, it is clear that there are benefits to consuming this mushroom, but to 
what extent these treatments provide benefits is still left to be seen.  The relationship between the 
histones observed in this study and the fungal extract provides a small, yet novel benefit to the 
differentiation process in stem cells.  With protocol refinement, H. erinaceus might be used in 
the future as a supplement to growth media when differentiating cells. 
It is worth noting that we did have limitations that future studies can avoid when 
attempting to build upon this one.  To our knowledge, we were the first to attempt a quantitative 
and label-free proteomic analysis on rat neural stem cells after being treated with aqueous extract 
of H. erinaceus.  We did not find any previous studies that covered this exact topic; therefore, we 
did not have a specific guide on how to proceed flawlessly.  We were forced to pull information 
from many facets of the groups currently analyzing H. erinaceus and its effects.  We were also 
limited due to the sensitive nature of the neural stem cells.  We would have preferred to work 
with human tissue to analyze the medicinal benefits in a better way, but due to costs, our lab was 
limited to animal cells such as those from rats. These cells were cultured from a primary cell line 
59 
and, as a result, were very difficult to work with.  Having an immortal cell line would allow us 
more time and resources and we would not have to worry about running out of products.  It 
would have been less expensive and would have also allowed us to run the procedure for a 
longer period of time to witness the effects on a deeper level.  Running the experiment again for 
a longer period of time would be very useful in specifically seeing if MBP was indeed in the 
sample, but did not have enough time to build up to significant protein levels.  Previously 
successful studies have demonstrated progress when utilizing nerve growth factor in their 
experiments involving neural stem cells19. 
Although having a larger group working on analyzing and researching every protein in 
our data would have allowed us to deliver more insight on this topic, the results presented in this 
paper are of the best quality that was allowed due to our restrictions.  We are confident that this 
is a good first step through the door and that others will find this information helpful when 
proceeding with more sharpened procedures for analyzing the proteomic contents of rat neural 
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APPENDIX A: LIST OF T-TEST SIGNIFICANT PROTEINS AND FOLD CHANGES IN 
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APPENDIX C: LIST OF ANOVA SIGNIFICANT PROTEINS AND FOLD CHANGES IN 
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